+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
ID05429632

Efficacy and Safety Study of Mocravimod as Additional and Maintenance Treatment in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Led by Priothera SAS · Updated on 2026-10-30

366

Participants Needed

111

Research Sites

130 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the use of mocravimod as an additional and maintenance treatment for adults with acute myeloid leukemia AML who are undergoing allogeneic hematopoietic cell transplantation HCT. This phase III, multi-center, randomized, double-blind, placebo-controlled trial aims to assess the drugs safety and effectiveness in this patient population, focusing on improving relapse-free survival. Participants will be randomly assigned to one of three groups receiving 3 mg of mocravimod daily, 1 mg of mocravimod daily, or a placebo daily, all administered orally for 12 months. The study involves parallel groups and maintains quadruple masking to ensure unbiased results. During the trial, participants will be closely monitored with regular assessments to evaluate relapse-free survival over 12 months and overall survival over 24 months. Safety and efficacy will be observed throughout, with participants undergoing standard care alongside study treatments. The total participation duration aligns with the treatment and follow-up periods extending up to two years.

CONDITIONS

Brief Title

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Research Team

M

Malika Souquieres, MSc

J

Jens Hasskarl, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here